One Amino Acid, Three Destinies
Tryptophan is an essential amino acid obtained exclusively from diet (turkey, eggs, cheese, nuts, seeds). In the body, it is metabolised through three major pathways — and the gut microbiome influences all three. The balance between these pathways has implications for mood, immune regulation, and intestinal barrier integrity.
The Serotonin Pathway
Approximately 95 percent of the body's serotonin (5-HT) is produced in the gut by enterochromaffin (EC) cells, using tryptophan hydroxylase 1 (TPH1) to convert tryptophan to 5-HTP and then serotonin. Gut serotonin primarily regulates motility, secretion, and visceral sensation — it does not directly cross the blood-brain barrier to influence mood. However, by consuming tryptophan, the serotonin pathway reduces the availability of tryptophan for brain serotonin synthesis, creating an indirect competition between gut and brain.
The Kynurenine Pathway
The majority of dietary tryptophan (approximately 90 to 95 percent) is metabolised through the kynurenine pathway, primarily in the liver and immune cells. The rate-limiting enzyme, indoleamine 2,3-dioxygenase (IDO), is strongly upregulated by pro-inflammatory cytokines (IFN-γ, TNF-α). In chronic inflammatory states — including IBD, depression, and chronic infection — IDO activity increases, diverting tryptophan away from serotonin synthesis and toward kynurenine metabolites, some of which (quinolinic acid) are neurotoxic while others (kynurenic acid) are neuroprotective. This tryptophan 'steal' is proposed as one mechanism linking chronic inflammation to depression.
The Indole Pathway
Gut bacteria metabolise unabsorbed tryptophan into indole derivatives — including indole-3-propionic acid (IPA), indole-3-aldehyde (IAld), and indole-3-acetic acid (IAA). These microbial metabolites activate the aryl hydrocarbon receptor (AhR) on intestinal immune cells and epithelial cells, promoting IL-22 production (which strengthens the gut barrier), enhancing antimicrobial peptide secretion, and supporting regulatory immune responses. Reduced microbial indole production has been documented in IBD and IBS patients, suggesting that this pathway contributes to barrier dysfunction in these conditions.
Clinical Implications
The tryptophan-microbiome nexus has therapeutic implications. In IBD, restoring microbial indole production (through dietary or prebiotic interventions) could improve barrier function. In depression associated with chronic inflammation, targeting the kynurenine pathway (IDO inhibitors) or supporting gut microbial tryptophan metabolism are active areas of research. For IBS patients with comorbid depression, the competition between gut serotonin production and brain tryptophan availability provides a mechanistic rationale for integrated gut-brain treatment approaches.
Practical Notes
Dietary tryptophan adequacy (recommended daily intake approximately 250 to 425 milligrams) supports all three metabolic pathways. Foods rich in tryptophan — poultry, eggs, fish, dairy, nuts, seeds, legumes — should be included in a balanced diet. However, tryptophan supplementation (particularly in isolation) should be approached with caution due to potential serotonin syndrome risk when combined with SSRIs or MAOIs.